Dyne Therapeutics Future Growth

Future criteria checks 0/6

Dyne Therapeutics is forecast to grow earnings and revenue by 2.9% and 72% per annum respectively. EPS is expected to grow by 14.6% per annum. Return on equity is forecast to be -168.2% in 3 years.

Key information

2.9%

Earnings growth rate

14.6%

EPS growth rate

Biotechs earnings growth	24.0%
Revenue growth rate	72.0%
Future return on equity	-168.2%
Analyst coverage	Good
Last updated	03 May 2024

Recent future growth updates

Recent updates

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dec 10

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Aug 26

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Jul 12

Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251

Jul 05

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 05

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Jan 12

We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth

Sep 29

Dyne Therapeutics' chief scientific officer Romesh Subramanian steps down

Jun 02

Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 12

Dyne Therapeutics EPS beats by $0.10

May 06

Could The Dyne Therapeutics, Inc. (NASDAQ:DYN) Ownership Structure Tell Us Something Useful?

Jan 27

Dyne Therapeutics posts encouraging data from its pre-clinical myotonic dystrophy trial

Jan 11

Beneficiary Dyne Therapeutics rises on competitor Sarepta's miss in DMD trial

Jan 08

Earnings and Revenue Growth Forecasts

NasdaqGS:DYN - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	28	-380	-328	-330	1
12/31/2025	N/A	-292	-246	-265	2
12/31/2024	N/A	-259	-236	-212	9
3/31/2024	N/A	-257	-220	-220	N/A
12/31/2023	N/A	-236	-189	-188	N/A
9/30/2023	N/A	-208	-184	-182	N/A
6/30/2023	N/A	-189	-176	-175	N/A
3/31/2023	N/A	-177	-152	-150	N/A
12/31/2022	N/A	-168	-157	-154	N/A
9/30/2022	N/A	-181	-157	-153	N/A
6/30/2022	N/A	-182	-141	-137	N/A
3/31/2022	N/A	-160	-157	-152	N/A
12/31/2021	N/A	-149	-123	-120	N/A
9/30/2021	N/A	-126	-114	-112	N/A
6/30/2021	N/A	-97	-98	-96	N/A
3/31/2021	N/A	-77	-59	-58	N/A
12/31/2020	N/A	-59	-48	-47	N/A
9/30/2020	N/A	-36	-32	-30	N/A
6/30/2020	N/A	-28	-23	-22	N/A
3/31/2020	N/A	-21	-18	-17	N/A
12/31/2019	N/A	-15	-13	-12	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: DYN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: DYN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: DYN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: DYN is forecast to have no revenue next year.

High Growth Revenue: DYN is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: DYN is forecast to be unprofitable in 3 years.

Dyne Therapeutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target increased by 8.3% to US$37.56

Price target increased by 9.6% to US$28.50

Price target decreased to US$24.67

Price target decreased to US$30.25

Recent updates

We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dyne Therapeutics, Inc., Annual General Meeting, May 22, 2024

Dyne Therapeutics, Inc. Announces Chief Executive Officer Changes

CEO, President & Director recently sold US$223k worth of stock

Chief Operating Officer recently sold US$725k worth of stock

Price target increased by 8.3% to US$37.56

Dyne: H2 2024 Muscle Disease Data Could Boost Value

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

CEO, President & Director notifies of intention to sell stock

Chief Business Officer exercised options and sold US$476k worth of stock

New major risk - Shareholder dilution

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.125 million.

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.125 million.

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $175 million.

Chief Business Officer notifies of intention to sell stock

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Chief Operating Officer notifies of intention to sell stock

New major risk - Financial position

CEO, President & Director notifies of intention to sell stock

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

New major risk - Financial position

Insufficient new directors

CEO, President & Director recently sold US$618k worth of stock

CEO, President & Director notifies of intention to sell stock

Dyne Therapeutics, Inc. Announces Resignation of Dr. Lawrence Klein as Board Member

Insufficient new directors

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Price target increased by 9.6% to US$28.50

Insider exercised options and sold US$133k worth of stock

Insider notifies of intention to sell stock

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dyne Therapeutics, Inc. Receives Fda Fast Track Designation for Dyne-251 for the Treatment of Duchenne Muscular Dystrophy

CEO, President & Director exercised options and sold US$2.4m worth of stock

Dyne Therapeutics, Inc. Presents Preclinical Data from Its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 At World Muscle Society 2022 Congress

Dyne Therapeutics, Inc. Prioritizes its Focus and Resources on its Clinical Programs, DYNE-101 in DM1 and DYNE-251 in DMD

Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne Therapeutics, Inc. Appoints Francesco Bibbiani as Senior Vice President, Head of Development

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Dyne Therapeutics, Inc. Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research

High number of new directors

Price target decreased to US$24.67

Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Dyne Therapeutics, Inc. Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251

Dyne Therapeutics, Inc. Presents New In Vivo Data from DYNE-101

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

High number of new directors

Dyne Therapeutics, Inc., Annual General Meeting, Jun 03, 2022

Price target decreased to US$30.25

Dyne Therapeutics, Inc. Appoints Carlo Inert, M.D., to Its Board of Directors

Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Dyne Therapeutics, Inc. Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscular Dystrophy

We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth

Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell 3000E Growth Index

Dyne Therapeutics, Inc. Presents Preclinical Data from Its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

Dyne Therapeutics' chief scientific officer Romesh Subramanian steps down

Dyne Therapeutics Presents New Preclinical Data from Myotonic Dystrophy Type 1 Program During American Society of Gene & Cell Therapy Annual Meeting

Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

Dyne Therapeutics EPS beats by $0.10

Dyne Therapeutics, Inc. Announces New Preclinical Data from Its Myotonic Dystrophy Type 1 Program Will Be Featured in Presentations During the American Society of Gene & Cell Therapy

Dyne Therapeutics, Inc. Appoints Wildon Farwell as Chief Medical Officer

New 90-day low: US$17.71

Dyne Therapeutics Appoints Ashish Dugar as Senior Vice President, Global Head of Medical Affairs

New 90-day low: US$18.40

Could The Dyne Therapeutics, Inc. (NASDAQ:DYN) Ownership Structure Tell Us Something Useful?

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $168 million.

Dyne Therapeutics, Inc. Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study

Dyne Therapeutics posts encouraging data from its pre-clinical myotonic dystrophy trial

New 90-day high: US$27.13